Mikael Dolsten's Insider Trades & SAST Disclosures
Mikael Dolsten's most recent trade in Agilent Technologies Inc. was a trade of 1,819 Common Stock done at an average price of $121.2 . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mikael Dolsten.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agilent Technologies Inc. | G. Mikael Dolsten | Director | Grant, award, or other acquisition of securities at price $ 121.18 per share. | 14 Mar 2025 | 1,819 | 7,549 (0%) | 0% | 121.2 | 220,426 | Common Stock |
| Pfizer Inc. | Mikael Dolsten | President R&D | 12 Sep 2024 | 137,760 | 0 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 12 Sep 2024 | 137,760 | 137,760 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 12 Sep 2024 | 126,794 | 126,794 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 12 Sep 2024 | 126,794 | 0 | - | - | Stock Appreciation Rights | ||
| Agilent Technologies Inc. | Mikael Dolsten | Director | Grant, award, or other acquisition of securities at price $ 147.48 per share. | 15 Mar 2024 | 1,678 | 5,711 (0%) | 0% | 147.5 | 247,471 | Common Stock |
| Pfizer Inc. | Dolsten Mikael | President R&D | 28 Feb 2024 | 21,437 | 321,729 (0%) | 0% | 27.0 | 579,656 | Common Stock | |
| Pfizer Inc. | Dolsten Mikael | President R&D | 27 Feb 2024 | 214,880 | 214,880 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 27 Feb 2024 | 189,867 | 189,867 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Dolsten Mikael | President R&D | 23 Feb 2024 | 24,822 | 343,166 (0%) | 0% | 27.8 | 689,059 | Common Stock | |
| Pfizer Inc. | Dolsten Mikael | President R&D | 15 Dec 2023 | 37,552 | 87,581 | - | - | Phantom Stock Units | ||
| Agilent Technologies Inc. | Mikael Dolsten | Director | Grant, award, or other acquisition of securities at price $ 136.82 per share. | 16 Mar 2023 | 1,658 | 4,018 (0%) | 0% | 136.8 | 226,848 | Common Stock |
| Pfizer Inc. | Mikael Dolsten | President R&D | 25 Feb 2023 | 37,078 | 354,145 (0%) | 0% | 41.8 | 1,548,007 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 22 Feb 2023 | 137,760 | 137,760 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 22 Feb 2023 | 119,894 | 119,894 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 22 Feb 2023 | 32,592 | 391,223 (0%) | 0% | 42.4 | 1,381,249 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 07 Nov 2022 | 133,430 | 0 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 07 Nov 2022 | 127,146 | 0 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 07 Nov 2022 | 50,938 | 391,837 (0%) | 0% | 30.2 | 1,536,799 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 07 Nov 2022 | 28,170 | 420,007 (0%) | 0% | 38.7 | 1,090,461 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 May 2022 | 32,015 | 333,342 (0%) | 0% | 49.3 | 1,578,660 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 May 2022 | 18,562 | 365,357 (0%) | 0% | 49.3 | 915,478 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 May 2022 | 15,167 | 27,380 | - | - | Phantom Stock Units SSP | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 May 2022 | 7,876 | 383,919 (0%) | 0% | 49.3 | 388,523 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 May 2022 | 2,891 | 391,795 (0%) | 0% | 49.4 | 142,671 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 May 2022 | 2,358 | 394,686 (0%) | 0% | 49.3 | 116,344 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 May 2022 | 200 | 397,044 (0%) | 0% | 49.4 | 9,872 | Common Stock | |
| Agilent Technologies Inc. | Mikael Dolsten | Director | Grant, award, or other acquisition of securities at price $ 136.82 per share. | 17 Mar 2022 | 1,785 | 2,352 (0%) | 0% | 136.8 | 244,224 | Common Stock |
| Pfizer Inc. | Mikael Dolsten | President R&D | 03 Mar 2022 | 158,331 | 0 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 03 Mar 2022 | 127,674 | 0 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 03 Mar 2022 | 62,022 | 356,140 (0%) | 0% | 27.3 | 1,695,681 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 03 Mar 2022 | 40,438 | 396,578 (0%) | 0% | 38.7 | 1,565,355 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 26 Feb 2022 | 29,744 | 294,118 (0%) | 0% | 47.7 | 1,419,384 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 23 Feb 2022 | 126,794 | 126,794 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 23 Feb 2022 | 111,516 | 111,516 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 23 Feb 2022 | 29,767 | 323,862 (0%) | 0% | 46.9 | 1,395,179 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 153,789 | 0 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 145,970 | 0 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 127,160 | 0 | - | - | Stock Appreciation Rights | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 76,135 | 216,093 (0%) | 0% | 22.9 | 1,742,730 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 64,841 | 280,934 (0%) | 0% | 27.3 | 1,772,753 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 58,572 | 339,506 (0%) | 0% | 25.6 | 1,499,443 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 47,828 | 71,314 | - | - | Phantom Stock Units | ||
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 36,711 | 279,842 (0%) | 0% | 50.3 | 1,845,829 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 6,708 | 316,553 (0%) | 0% | 50.3 | 337,614 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 5,227 | 323,261 (0%) | 0% | 50.3 | 262,866 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 3,396 | 328,488 (0%) | 0% | 50.3 | 170,853 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 3,197 | 331,884 (0%) | 0% | 50.3 | 160,777 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 2,301 | 335,081 (0%) | 0% | 50.3 | 115,786 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 11 Nov 2021 | 2,124 | 337,382 (0%) | 0% | 50.3 | 106,922 | Common Stock | |
| Agilent Technologies Inc. | Mikael Dolsten | Director | Grant, award, or other acquisition of securities at price $ 172.44 per share. | 22 Sep 2021 | 567 | 567 (0%) | 0% | 172.4 | 97,773 | Common Stock |
| Karyopharm Therapeutics Inc | Mikael Dolsten | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 23,900 | 23,900 | - | - | Nonstatutory Stock Option (right to buy) | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 27 Feb 2021 | 23,841 | 137,727 (0%) | 0% | 33.5 | 798,435 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 25 Feb 2021 | 28,271 | 161,568 (0%) | 0% | 33.8 | 956,125 | Common Stock | |
| Karyopharm Therapeutics Inc | Mikael Dolsten | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2020 | 16,400 | 16,400 | - | - | Nonstatutory Stock Option (right to buy) | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 18 May 2020 | 24,242 | 174,918 (0%) | 0% | 37.8 | 916,105 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 18 May 2020 | 17,357 | 199,160 (0%) | 0% | 37.8 | 655,747 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 18 May 2020 | 16,840 | 216,517 (0%) | 0% | 37.8 | 636,552 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 18 May 2020 | 14,727 | 233,357 (0%) | 0% | 37.8 | 556,239 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 18 May 2020 | 9,700 | 248,084 (0%) | 0% | 37.8 | 366,175 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 18 May 2020 | 6,470 | 257,784 (0%) | 0% | 37.8 | 244,631 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 18 May 2020 | 5,517 | 264,254 (0%) | 0% | 37.8 | 208,322 | Common Stock | |
| Pfizer Inc. | Mikael Dolsten | President R&D | 18 May 2020 | 500 | 269,771 (0%) | 0% | 37.8 | 18,910 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges